Antonio Benedetti

List of Publications by Year
in descending order

133	8,373	46918	48187
papers	citations	47 h-index	88 g-index

137	137	137	9720
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A prospective study of directâ€acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohort. Hepatology, 2022, 76, 220-232.	3.6	12
2	Therapeutic effects of dexamethasone-loaded hyaluronan nanogels in the experimental cholestasis. Drug Delivery and Translational Research, 2022, , 1.	3.0	0
3	Multicenter Validation of the DETAIL Questionnaire for the Screening of Spondyloarthritis in Patients With Inflammatory Bowel Diseases. Journal of Rheumatology, 2021, 48, 179-187.	1.0	9
4	The Management of Cholestatic Liver Diseases: Current Therapies and Emerging New Possibilities. Journal of Clinical Medicine, 2021, 10, 1763.	1.0	17
5	X Chromosome Contribution to the Genetic Architecture of Primary Biliary Cholangitis. Gastroenterology, 2021, 160, 2483-2495.e26.	0.6	27
6	Role of autophagy in cholangiocarcinoma: Pathophysiology and implications for therapy. World Journal of Clinical Cases, 2021, 9, 6234-6243.	0.3	2
7	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. Journal of Hepatology, 2021, 75, 572-581.	1.8	62
8	Gut epithelial impairment, microbial translocation and immune system activation in inflammatory bowel diseaseâ€“associated spondyloarthritis. Rheumatology, 2021, 60, 92-102.	0.9	18
9	Involvement of Autophagy in Ageing and Chronic Cholestatic Diseases. Cells, 2021, 10, 2772.	1.8	4
10	Aging and the Biological Response to Liver Injury. Seminars in Liver Disease, 2020, 40, 225-232.	1.8	13
11	Locally acquired hepatitis E virus in Marche Italy: Clinical/laboratory features and outcome. Digestive and Liver Disease, 2020, 52, 434-439.	0.4	4
12	mTOR and STAT3 Pathway Hyper-Activation is Associated with Elevated Interleukin-6 Levels in Patients with Shwachman-Diamond Syndrome: Further Evidence of Lymphoid Lineage Impairment. Cancers, 2020, 12, 597.	1.7	7
13	Gutâ€“Liver Axis and Inflammasome Activation in Cholangiocyte Pathophysiology. Cells, 2020, 9, 736.	1.8	20
14	Research Strands in Dermatology and Gastroenterology Units of Department of Clinical and Molecular Sciences in Polytechnic Marche University. , 2020, , 221-246.		0
15	Clinical and patient reported outcomes of the multidisciplinary management in patients with inflammatory bowel disease-associated spondyloarthritis. European Journal of Internal Medicine, 2019, 64, 76-84.	1.0	9
16	Agingâ€Related Expression of Twinfilinâ€1 Regulates Cholangiocyte Biological Response to Injury. Hepatology, 2019, 70, 883-898.	3.6	9
17	Aging-Related Molecular Pathways in Chronic Cholestatic Conditions. Frontiers in Medicine, 2019, 6, 332.	1.2	9
18	The DETection of Arthritis in Inflammatory boweL diseases (DETAIL) questionnaire: development and preliminary testing of a new tool to screen patients with inflammatory bowel disease for the presence of spondyloarthritis. Clinical Rheumatology, 2018, 37, 1037-1044.	1.0	28

#	Article	IF	Citations
19	Inflammation and the Gut-Liver Axis in the Pathophysiology of Cholangiopathies. International Journal of Molecular Sciences, 2018, 19, 3003.	1.8	29
20	Postoperative Recurrence of Crohn's Disease: Pathophysiology, Diagnosis and Treatment. Current Pharmaceutical Biotechnology, 2018, 18, 979-988.	0.9	8
21	Nlrp3 Activation Induces Il-18 Synthesis and Affects the Epithelial Barrier Function in Reactive Cholangiocytes. American Journal of Pathology, 2017, 187, 366-376.	1.9	43
22	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. The Lancet Gastroenterology and Hepatology, 2017, 2, 427-434.	3.7	15
23	Current Targets for Primary Sclerosing Cholangitis. Current Drug Targets, 2017, 18, 901-907.	1.0	0
24	Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nature Reviews Gastroenterology and Hepatology, 2016, 13, 261-280.	8.2	964
25	Hepatitis E in a region of Italy: An emerging autochthonous infection?. Digestive and Liver Disease, 2016, 48, 1340-1345.	0.4	11
26	Mycosis Fungoidesâ€"like Eruption and Infliximab. Journal of Clinical Gastroenterology, 2016, 50, 610-611.	1.1	3
27	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	6.1	91
28	PDX-1 mRNA expression in endoscopic ultrasound-guided fine needle cytoaspirate: Perspectives in the diagnosis of pancreatic cancer. Digestive and Liver Disease, 2015, 47, 138-143.	0.4	8
29	HCC Development Is Associated to Peripheral Insulin Resistance in a Mouse Model of NASH. PLoS ONE, 2014, 9, e97136.	1.1	76
30	Activation of the developmental pathway neurogenin-3/microRNA-7a regulates cholangiocyte proliferation in response to injury. Hepatology, 2014, 60, 1324-1335.	3.6	22
31	VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICEâ€1 study. International Journal of Cancer, 2014, 135, 1247-1256.	2.3	109
32	The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management. BMC Cancer, 2014, 14, 110.	1.1	80
33	Pegylated interferon Î± plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. Digestive and Liver Disease, 2014, 46, 826-832.	0.4	12
34	Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology, 2014, 59, 1738-1749.	3.6	258
35	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. Digestive and Liver Disease, 2014, 46, 579-589.	0.4	40
36	Tacrolimus and Everolimus De Novo versus Minimization of Standard Dosage of Tacrolimus Provides a Similar Renal Function at One Year after Liver Transplantation: A Case-Control Matched-Pairs Analysis. Annals of Transplantation, 2014, 19, 545-550.	0.5	6

#	Article	IF	Citations
37	PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: Possible implications for sclerosing cholangitis. Journal of Hepatology, 2013, 58, 750-756.	1.8	24
38	Liver carcinogenesis: Rodent models of hepatocarcinoma and cholangiocarcinoma. Digestive and Liver Disease, 2013, 45, 450-459.	0.4	87
39	Semaphorin 7A Contributes to TGF-Î²â€“Mediated Liver Fibrogenesis. American Journal of Pathology, 2013, 183, 820-830.	1.9	46
40	Doxorubicin-eluting beadvsconventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. World Journal of Gastroenterology, 2013, 19, 5622.	1.4	52
41	The significance of genetics for cholangiocarcinoma development. Annals of Translational Medicine, 2013, 1, 28.	0.7	20
42	Angiogenic factors in chronic liver diseases: the effects on hepatic progenitor cells. Hepatobiliary Surgery and Nutrition, 2013, 2, 61-4.	0.7	1
43	New insights in hepatocellular carcinoma: from bench to bedside. Annals of Translational Medicine, 2013, 1, 15.	0.7	12
44	Endoplasmic Reticulum stress induces hepatic stellate cell apoptosis and contributes to fibrosis resolution. Liver International, 2012, 32, 1574-1584.	1.9	40
45	An oestrogen receptor Î²-selective agonist exerts anti-neoplastic effects in experimental intrahepatic cholangiocarcinoma. Digestive and Liver Disease, 2012, 44, 134-142.	0.4	34
46	Preoperative Work-up: Endoscopy and Endoscopic Ultrasonography. , 2012, , 43-49.		0
47	Cholangiocarcinoma in Italy: A national survey on clinical characteristics, diagnostic modalities and treatment. Results from the â€œCholangiocarcinomaâ€•committee of the Italian Association for the Study of Liver disease. Digestive and Liver Disease, 2011, 43, 60-65.	0.4	59
48	Glucagonâ€like peptideâ€1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a highâ€fat diet in nonalcoholic steatohepatitis. Liver International, 2011, 31, 1285-1297.	1.9	337
49	Preface. Transplantation Proceedings, 2011, 43, 949.	0.3	0
50	Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut, 2011, 60, 108-115.	6.1	30
51	Increased local dopamine secretion has growthâ€promoting effects in cholangiocarcinoma. International Journal of Cancer, 2010, 126, 2112-2122.	2.3	46
52	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nature Genetics, 2010, 42, 658-660.	9.4	389
53	Clinical implications of novel aspects of biliary pathophysiology. Digestive and Liver Disease, 2010, 42, 238-244.	0.4	16
54	Pancreatic Duodenal Homeobox-1 de novo expression drives cholangiocyte neuroendocrine-like transdifferentiation. Journal of Hepatology, 2010, 53, 663-670.	1.8	14

#	Article	IF	Citations
55	Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. Journal of Experimental and Clinical Cancer Research, 2010, 29, 164.	3.5	39
56	Ethyl caffeate from Verdicchio wine: Chromatographic purification and in vivo evaluation of its antifibrotic activity. Journal of Separation Science, 2009, 32, 3585-3590.	1.3	12
57	Control of Cholangiocyte Adaptive Responses by Visceral Hormones and Neuropeptides. Clinical Reviews in Allergy and Immunology, 2009, 36, 13-22.	2.9	28
58	Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. Liver International, 2009, 29, 1031-1042.	1.9	33
59	Serotonin Metabolism Is Dysregulated in Cholangiocarcinoma, which Has Implications for Tumor Growth. Cancer Research, 2008, 68, 9184-9193.	0.4	90
60	Leptin Enhances Cholangiocarcinoma Cell Growth. Cancer Research, 2008, 68, 6752-6761.	0.4	77
61	Hedgehog signaling regulates epithelial-mesenchymal transition during biliary fibrosis in rodents and humans. Journal of Clinical Investigation, 2008, 118, 3331-42.	3.9	284
62	The Î±₂-adrenergic receptor agonist UK 14,304 inhibits secretin-stimulated ductal secretion by downregulation of the cAMP system in bile duct-ligated rats. American Journal of Physiology - Cell Physiology, 2007, 293, C1252-C1262.	2.1	30
63	Thyroid hormone inhibits biliary growth in bile duct-ligated rats by PLC/IP3/Ca2+-dependent downregulation of SRC/ERK1/2. American Journal of Physiology - Cell Physiology, 2007, 292, C1467-C1475.	2.1	19
64	Serum and Biliary Insulin-like Growth Factor I and Vascular Endothelial Growth Factor in Determining the Cause of Obstructive Cholestasis. Annals of Internal Medicine, 2007, 147, 451.	2.0	52
65	Molecular pathology of biliary tract cancers. Cancer Letters, 2007, 250, 155-167.	3.2	45
66	Endogenous opioid peptides and chronic liver disease: From bedside to bench. Journal of Hepatology, 2007, 46, 583-586.	1.8	22
67	Vitamin E in Chronic Liver Diseases and Liver Fibrosis. Vitamins and Hormones, 2007, 76, 551-573.	0.7	36
68	Glucagon-Like Peptide-1 and Its Receptor Agonist Exendin-4 Modulate Cholangiocyte Adaptive Response to Cholestasis. Gastroenterology, 2007, 133, 244-255.	0.6	73
69	Prolactin stimulates the proliferation of normal female cholangiocytes by differential regulation of Ca2+-dependent PKC isoforms. BMC Physiology, 2007, 7, 6.	3.6	35
70	Cytoprotective effects of taurocholic acid feeding on the biliary tree after adrenergic denervation of the liver. Liver International, 2007, 27, 558-568.	1.9	23
71	Novel interaction of bile acid and neural signaling in the regulation of cholangiocyte function. Hepatology Research, 2007, 37, S420-9.	1.8	6
72	Taurocholic acid feeding prevents tumor necrosis factor-alpha-induced damage of cholangiocytes by a PI3K-mediated pathway. Experimental Biology and Medicine, 2007, 232, 942-9.	1.1	12

#	Article	IF	Citations
73	Ca2+-Dependent Cytoprotective Effects of Ursodeoxycholic and Tauroursodeoxycholic Acid on the Biliary Epithelium in a Rat Model of Cholestasis and Loss of Bile Ducts. American Journal of Pathology, 2006, 168, 398-409.	1.9	68
74	Estrogens and Insulin-Like Growth Factor 1 Modulate Neoplastic Cell Growth in Human Cholangiocarcinoma. American Journal of Pathology, 2006, 169, 877-888.	1.9	136
75	A Model of Insulin Resistance and Nonalcoholic Steatohepatitis in Rats. American Journal of Pathology, 2006, 169, 846-860.	1.9	237
76	Endogenous Opioids Modulate the Growth of the Biliary Tree in the Course of Cholestasis. Gastroenterology, 2006, 130, 1831-1847.	0.6	41
77	Estrogens maintain bile duct mass and reduce apoptosis after biliodigestive anastomosis in bile duct ligated rats. Journal of Hepatology, 2006, 44, 1158-1166.	1.8	16
78	Ethyl caffeoate: Liquid chromatographyâ€“tandem mass spectrometric analysis in Verdicchio wine and effects on hepatic stellate cells and intracellular peroxidation. Analytica Chimica Acta, 2006, 563, 375-381.	2.6	5
79	Adrenergic receptor agonists prevent bile duct injury induced by adrenergic denervation by increased cAMP levels and activation of Akt. American Journal of Physiology - Renal Physiology, 2006, 290, G813-G826.	1.6	55
80	Cell proliferation and drug resistance in hepatocellular carcinoma are modulated by Rho GTPase signals. American Journal of Physiology - Renal Physiology, 2006, 290, G624-G632.	1.6	28
81	Nervous and Neuroendocrine regulation of the pathophysiology of cholestasis and of biliary carcinogenesis. World Journal of Gastroenterology, 2006, 12, 3471.	1.4	25
82	Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology, 2005, 41, 1074-1084.	3.6	210
83	Early response of Î±2(I) collagen to acetaldehyde in human hepatic stellate cells is TGF-Î² independent. Hepatology, 2005, 42, 343-352.	3.6	77
84	Î³-Aminobutyric Acid Inhibits Cholangiocarcinoma Growth by Cyclic AMPâ€“Dependent Regulation of the Protein Kinase A/Extracellular Signal-Regulated Kinase 1/2 Pathway. Cancer Research, 2005, 65, 11437-11446.	0.4	85
85	Autocrine/paracrine regulation of the growth of the biliary tree by the neuroendocrine hormone serotonin. Gastroenterology, 2005, 128, 121-137.	0.6	226
86	Bile acids induce hepatic stellate cell proliferation via activation of the epidermal growth factor receptor. Gastroenterology, 2005, 128, 1042-1055.	0.6	135
87	Nerve growth factor modulates the proliferative capacity of the intrahepatic biliary epithelium in experimental cholestasis. Gastroenterology, 2004, 127, 1198-1209.	0.6	87
88	cAMP stimulates the secretory and proliferative capacity of the rat intrahepatic biliary epithelium through changes in the PKA/Src/MEK/ERK1/2 pathway. Journal of Hepatology, 2004, 41, 528-537.	1.8	110
89	Î±-1 adrenergic receptor agonists modulate ductal secretion of BDL rats via Ca2+- and PKC-dependent stimulation of cAMP. Hepatology, 2004, 40, 1116-1127.	3.6	61
90	Selective Na+/H+ exchange inhibition by cariporide reduces liver fibrosis in the rat. Hepatology, 2003, 37, 256-266.	3.6	44

#	Article	IF	Citations
91	Regulation of ERK/JNK/p70S6K in two rat models of liver injury and fibrosis. Journal of Hepatology, 2003, 39, 528-537.	1.8	48
92	Development and characterization of secretin-stimulated secretion of cultured rat cholangiocytes. American Journal of Physiology - Renal Physiology, 2003, 284, G1066-G1073.	1.6	25
93	Taurocholate prevents the loss of intrahepatic bile ducts due to vagotomy in bile duct-ligated rats. American Journal of Physiology - Renal Physiology, 2003, 284, G837-G852.	1.6	46
94	Taurocholate feeding prevents CCl₄-induced damage of large cholangiocytes through PI3-kinase-dependent mechanism. American Journal of Physiology - Renal Physiology, 2003, 284, G290-G301.	1.6	35
95	Rearrangement of the cytoskeletal network induced by platelet-derived growth factor in rat hepatic stellate cells: role of different intracellular signalling pathways. Journal of Hepatology, 2002, 36, 179-190.	1.8	22
96	Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. Journal of Hepatology, 2002, 37, 584-591.	1.8	120
97	Insulin inhibits secretin-induced ductal secretion by activation of PKC alpha and inhibition of PKA activity. Hepatology, 2002, 36, 641-651.	3.6	55
98	Inhibition of the Na+/H+ exchanger reduces rat hepatic stellate cell activity and liver fibrosis: An in vitro and in vivo study. Gastroenterology, 2001, 120, 545-556.	0.6	82
99	Intracellular pH regulation and Na + /H + exchange activity in human hepatic stellate cells: effect of platelet-derived growth factor, insulin-like growth factor 1 and insulin. Journal of Hepatology, 2001, 34, 378-385.	1.8	35
100	Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver, 2001, 21, 1-12.	0.1	133
101	Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. Hepatology, 2001, 33, 1130-1140.	3.6	119
102	Gastrin inhibits cholangiocyte growth in bile ductâ€“ligated rats by interaction with cholecystokinin-B/gastrin receptors viaD -myo-inositol 1,4,5-triphosphateâ€“, Ca2+-, and protein kinase Cî±â€“dependent mechanisms. Hepatology, 2000, 32, 17-25.	3.6	96
103	The function of alkaline phosphatase in the liver: Regulation of intrahepatic biliary epithelium secretory activities in the rat. Hepatology, 2000, 32, 174-184.	3.6	67
104	Corticosteroids modulate the secretory processes of the rat intrahepatic biliary epithelium. Gastroenterology, 2000, 118, A930.	0.6	1
105	Acute carbon tetrachloride feeding induces damage of large but not small cholangiocytes from BDL rat liver. American Journal of Physiology - Renal Physiology, 1999, 276, G1289-G1301.	1.6	94
106	Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Thl-like response in chronic hepatitis C. Liver International, 1999, 19, 212-219.	1.9	69
107	The significance of apoptosis in the liver. Liver International, 1999, 19, 453-463.	1.9	24
108	Acute carbon tetrachloride feeding selectively damages large, but not small, cholangiocytes from normal rat liver. Hepatology, 1999, 29, 307-319.	3.6	105

#	Article	IF	Citations
109	Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: Differential effects on signal transduction pathways. Hepatology, 1999, 29, 1743-1751.	3.6	293
110	The Na+/H+ exchanger modulates the fibrogenic effect of oxidative stress in rat hepatic stellate cells. Journal of Hepatology, 1999, 30, 868-875.	1.8	69
111	Intracellular pathways mediating Na+/H+ exchange activation by platelet-derived growth factor in rat hepatic stellate cells. Gastroenterology, 1999, 116, 1155-1166.	0.6	53
112	Cholinergic system modulates growth, apoptosis, and secretion of cholangiocytes from bile ductâ€“ligated rats. Gastroenterology, 1999, 117, 191-199.	0.6	155
113	Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology, 1998, 27, 720-726.	3.6	260
114	A morphometric study of the epithelium lining the rat intrahepatic biliary tree. Journal of Hepatology, 1996, 24, 335-342.	1.8	74
115	Regulation of Intracellular pH in Periportal and Perivenular Hepatocytes Isolated from Ethanol-Treated Rats. Alcoholism: Clinical and Experimental Research, 1995, 19, 216-225.	1.4	3
116	Effect of Brefeldin A on transcytotic vesicular pathway and bile secretion: A study on the isolated perfused rat liver and isolated rat hepatocyte couplets. Hepatology, 1995, 21, 450-459.	3.6	10
117	Functional and ultrastructural features of ethanol/bile salts interaction in the isolated perfused rat liver. Hepatology, 1995, 21, 1120-1129.	3.6	13
118	Brefeldin a inhibits the transcytotic vesicular transport of horseradish peroxidase in intrahepatic bile ductules isolated from rat liver. Hepatology, 1995, 22, 194-201.	3.6	3
119	Transforming growth factorÎ²1 increases the number of apoptotic bodies and decreases intracellular pH in isolated periportal and perivenular rat hepatocytes. Hepatology, 1995, 22, 1488-1498.	3.6	22
120	Transforming growth factor?1 increases the number of apoptotic bodies and decreases intracellular pH in isolated periportal and perivenular rat hepatocytes*1, *2. Hepatology, 1995, 22, 1488-1498.	3.6	1
121	Functional and ultrastructural features of ethanol/bile salts interaction in the isolated perfused rat liver. Hepatology, 1995, 21, 1120-1129.	3.6	1
122	Chronic ethanol feeding increases apoptosis and cell proliferation in rat liver. Journal of Hepatology, 1994, 20, 508-513.	1.8	84
123	Immunohistochemical analysis of Sâ€phase cells in normal human and rat liver by PC10 monoclonal antibody. Liver, 1994, 14, 57-64.	0.1	27
124	Tubulovesicular transcytotic pathway in rat biliary epithelium: A study in perfused liver and in isolated intrahepatic bile duct. Hepatology, 1993, 18, 422-432.	3.6	17
125	Regulation of intracellular pH in isolated periportal and perivenular rat hepatocytes. Gastroenterology, 1993, 105, 1797-1805.	0.6	16
126	Quantitative analysis of proliferating sinusoidal cells in dimethylnitrosamine-induced cirrhosis. Journal of Hepatology, 1992, 15, 361-366.	1.8	45

#	Article	IF	Citations
127	Evidence that plasma membrane fluidity of isolated hepatocytes is modified by exposure to microtubule-depolymerizing drugs. Journal of Hepatology, 1990, 10, 144-148.	1.8	13
128	Quantitative study of apoptosis in normal rat gastroduodenal mucosa. Journal of Gastroenterology and Hepatology (Australia), 1990, 5, 369-374.	1.4	26
129	Plasma membrane fluidity in isolated rat hepatocytes: A comparative study using DPH and TMA-DPH as fluorescent probes. Journal of Gastroenterology and Hepatology (Australia), 1989, 4, 221-227.	1.4	8
130	Age and sex related changes of plasma membrane fluidity in isolated rat hepatocytes. Biochemical and Biophysical Research Communications, 1988, 156, 840-845.	1.0	19
131	Subcellular changes and apoptosis induced by ethanol in rat liver. Journal of Hepatology, 1988, 6, 137-143.	1.8	97
132	Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liver. Journal of Hepatology, 1988, 7, 319-324.	1.8	81
133	Gastrointestinal disorders as immune-related adverse events. Exploration of Targeted Anti-tumor Therapy, 0, , .	0.5	2